For example, delivery of biological heterobifunctional degraders for STAT3 can shift the tumor microenvironment toward an anti-tumor state, either by redirecting tumor-associated macrophages toward the inflammatory M1 type macrophages or by inducing stromal cells to produce inflammatory cytokines.80 This could also synergize with immune checkpoint therapies, such as anti-PD-1 or anti-PD-L1. This evidence concerns the gene CD274 and neoplasm.